Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluzoparib Capsules in Healthy Volunteers
NCT04521192Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluzoparib in ovarian cancer (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Observed Plasma Concentration at Day 10 and Area Under the Plasma Concentration at Day 10. Started May 2019; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04521192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521192.